Published: 2022-11-23

Expression of DOG 1 and correlation with Ki-67 and tumor characteristics in GIST: case series analysis in a tertiary care center

Danita G. S. Edwin, Nithin Diwagar K., Ganthimathy Sekhar


Gastrointestinal stromal tumours (GISTs) are the most common non epithelial, mesenchymal tumours of the gastrointestinal tract and amount to 1 to 3% of all gastrointestinal tumours. Histologically, GISTs demonstrate considerable morphologic variation. The aim of the study was to evaluate the histo-morphological features of GIST and the expression of DOG1 and KI-67 in these tumours. Eleven cases of GISTs received during a five-year period at a tertiary care centre were analysed for their demographic parameters, morphology and risk stratification. Immunohistochemistry for DOG1 and Ki67 was performed for all the eleven cases. In this study there was a female preponderance with the mid -fifties being the median age of presentation. The stomach and small intestine were the common sites of involvement. The histologic type was predominantly spindle cell with a few cases of mixed tumours. DOG 1 was positive in all the tumours and Ki-67 index was markedly elevated in the epithelioid cell type and in the high-risk category of tumours. DOG 1 holds good as an important marker for clinically suspected GIST diagnosis and Ki-67 expression correlates with the risk stratification of the tumour and can be a good prognostic factor.


GIST, DOG1, Ki-67

Full Text:



Sbaraglia M, Businello G, Bellan E, Fassan M, Dei Tos AP. Mesenchymal tumours of the gastrointestinal tract. Pathologica. 2021;113(3):230.

Alshok MM. A clinical study on GIST in Babylon. 2020;1(53):001-5.

ŞAhin S, Ekinci Ö, SEçkin S, DUrSUn A. The diagnostic and prognostic utility of DOG1 expression on gastrointestinal stromal tumors. Turk Patoloji Derg. 2017;33(1):1-8.

Hirota S. Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry. Translational Gastroenterol Hepatol. 2018;3.

Rizzo FM, Palmirotta R, Marzullo A, Resta N, Cives M, Tucci M et al. Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer. 2016;16:87.

Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS et al. TMEM16A induces APK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012;72:3270-81.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T et al. DOG1 regulatesgrowth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013;73:3661-70.

Mantese, George Gastrointestinal stromal tumor. Curr Opinion Gastroenterol. 2019;35(6):555-9.

Xiao CC, Zhang S, Wang MH, Huang LY, Wu P, Xu Y et al. Clinicopathological features and prognostic factors of rectal gastrointestinal stromal tumors. J Gastrointest Surg. 2013;17:793-8.

Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology. 2003;226:527-32.

Tryggvason G, Kristmundsson T, Orvar K, Jónasson JG, Magnússon MK, Gíslason HG. Clinical study on gastrointestinal stromal tumors (GIST) in iceland, 1990-2003. Dig Dis Sci. 2007;52:2249-53.

Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005;103:821-9.

King DM. The radiology of gastrointestinal stromal tumours (GIST). Cancer Imaging. 2005;5(1):150.

Lee CH, Liang CW, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anatomic Pathol. 2010;17(3):222-32.

Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): comparison between 2 different antibodies. Appl Immunohistochem Molecular Morphol. 2010;18(4):333-7.

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surgical Pathol. 2002;10(2):81-9.

Artigiani Neto R, Logullo AF, Stávale JN, Lourenço LG. Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST). Acta Cir Bras. 2012;27:315-21.

Panizo-Santos A, Sola I, Vega F, de Alava E, Lozano MD, Idoate MA et al. Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol. 2000;8:133-44.

Noguchi T, Sato T, Takeno S, Uchida Y, Kashima K, Yokoyama S et al. Biological analysis of gastrointestinal stromal tumors. Oncol Rep. 2002;9:1277-82.

Belev B, Brèiæ I, Prejac J, Golubiæ ZA, Vrbanec D, Božikov J et al. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World J Gastroenterol 2013;19:523-7.

Fletcher CD, Berman JJ, Corless C, Gorstein F. Lasota 9. J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33(5):459-65.

DeMatteo. Two hundred gastrointestinal stromal tumours; recurrence patterns and prognostic factors for survival, Annals of Surgery. 2000;231(1):51-8

Arber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156-63.